We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Keryx Biopharmaceuticals has announced the initiation of its pivotal
Phase III and Phase IV clinical program with KRX-101 (oral sulodexide gelcap),
the company's lead drug candidate, for the treatment of diabetic nephropathy.
Callisto has announced that the Office of Orphan Products Development of the
FDA has granted orphan drug designation to the company's drug candidate Annamycin
for the treatment of acute lymphoblastic leukemia.
PPD has announced the signing of an agreement to exclusively license
to Duke University the development rights to PPD's patented portfolio of geranylgeranyl
transferase (GGTase) inhibitor compounds.
Peregrine presented new data at the Biotechnology Industry Organization
2005 (BIO 2005) annual meeting in Philadelphia, Pa., supporting the broad anti-viral
potential of Tarvacin.
Metabasis Therapeutics and Merck recently said they agreed to jointly research,
develop and market small-molecule therapies to treat conditions including diabetes,
high cholesterol and obesity.
Quigley has obtained the results from a series of in-vivo inflammation studies
conducted at a leading university research center of a potential broad-spectrum
anti-inflammatory, all natural, botanical compound (QR440).
ImmunoGen, has announced the initiation of patient dosing with its
huC242-DM4 Tumor-Activated Prodrug (TAP) compound, which is in development for
the treatment of colorectal, pancreatic, and other cancers that express the
CanAg antigen targeted by the compound.
Inspire Pharmaceuticals has announced recent developments in its
cystic fibrosis (CF) program, including three presentations made by Inspire
executives at the 28th European Cystic Fibrosis Society Conference held June
22 to 25 in Crete, Greece.
Theravance announced the results of a Phase II clinical study designed to assess
the bronchodilator duration, safety and tolerability of the investigational,
inhaled bronchodilator, GSK159797, the lead compound in the Beyond Advair collaboration
with GlaxoSmithKline (GSK).